The presence of residual activated coagulation factor XI (FXIa) in some commercial intravenous immunoglobulin (IVIG) products has been identified as the root cause of a small number of thromboembolic events in patients who had received such therapy. Our objectives here were to design and evaluate the manufacturing process of GC5107. a 10% glycine-stabilized IVIG product. for its capac... https://macorners.shop/product-category/custom-shaped-pillow/